Efficiency and safety of terlipressin application during caesarian section in pregnant women with a high risk of bleeding: A multicenter comprehensive cohort study of terli-bleed. part i

Prevention of postpartum haemorrhage is one of the important tasks of modern obstetrics, anesthesiology and intensive care. Objective. To assess the efficacy and safety of terlipressin usage as a means of postpartum haemorrhage development prevention during caesarean section in high-risk pregnant women. Patients and methods. From February to December 2020, a multicenter comprehensive cohort study, in which 5 medical centers participated, was conducted. The study included 454 pregnant women who underwent caesarean section and who were divided into two groups: control group I (n = 351) and study group II (n = 103), with the use of terlipressin injected into myometrium. Evaluation of the preventive effect of the drug was carried out in several main directions: the volume of blood loss, the need for additional methods of surgical hemostasis, the safety of intraoperative use. Results. Considerable differences were found in the assessment of significant risk factors for the development of postpartum haemorrhage, associated pathologies and comorbidity between the groups. The study group turned out to be more threatened by the postpartum haemorrhage development. In the control group, additional measures of surgical hemostasis were more often used, including hysterectomy (2.6% versus 1.9%) and relaparotomy (1.9% versus 1%). The median blood loss was statistically lower in the study group (700 ml versus 800 ml). Nevertheless, the considerable spread of data on the volume of blood loss should be noted, with a maximum blood loss of 10,000 ml in the control group and 4,500 ml in the study group. There were no serious complications in both groups. Conclusion. The study showed that the use of terlipressin can reduce the volume of blood loss in women with high risk factors for postpartum haemorrhage, as well as reduce the number of hysterectomies and relaparotomies. It is necessary to continue the prospective part of the study with an increase in the randomized sample of patients. © 2021, Dynasty Publishing House. All rights reserved.

Raspopin Y.S.1, 2 , Shifman E.M. 3 , Belinina A.A.4 , Rostovtsev A.V.5 , Artymuk N.V.6 , Olenev A.S. 7, 8 , Tskhai V.B.2, 9 , Аleksandrovich Yu.S.10 , Molchanova I.V.4 , Novikova O.N.6
Dynasty Publishing House
Номер выпуска
  • 1 Krasnoyarsk Regional Clinical Center of Maternal and Child Health, Krasnoyarsk, Russian Federation
  • 2 Prof. V.F.Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation
  • 3 M.F. Vladimirsky Moscow Regional Research and Clinical Institute (MONIKI), 61/2 Schepkin str, Moscow, 129110, Russian Federation
  • 4 Altai Regional Clinical Perinatal Center, Barnaul, Russian Federation
  • 5 Voronezh Сity Сlinical Emergency Hospital No 8, Voronezh, Russian Federation
  • 6 Kemerovo State Medical University, Kemerovo, Russian Federation
  • 7 City Clinical Hospital No 24, Moscow, Russian Federation
  • 8 Medical Institute of the Peoples’ Friendship University of Russia, Moscow, Russian Federation
  • 9 Federal Medical-Biological Agency of Russia, Krasnoyarsk, Russian Federation
  • 10 Saint Petersburg State Pediatric Medical University, Saint-Petersburg, Russian Federation
Ключевые слова
Caesarean section; Obstetric haemorrhage; Terlipressin
Дата создания
Дата изменения
Постоянная ссылка

Другие записи